Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation

NCT ID: NCT03431844

Last Updated: 2020-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

106 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective of the study is to clarify humanin-like peptide concentration in myocard tissue and in blood and to study if its concentration level is related to early complication occurrence and frequency after cardiac operation.

Hypothesis of the study is that previously described elements are related to each other.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data collection: Historical medical and preoperative data, operation data (type of operation performed and its details), detailed postoperative course (occurrence of complications).

Specimen collection:

* Tissue sample is taken during the operation from the right atrial appendage of the heart and the sample is frozen at -80 C.
* Blood samples are taken just before the operation, one hour after aortic cross-clamp removal and the next morning after the operation. Samples are processed and blood plasma is frozen at -80 C.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Ischemia Coronary Artery Bypass Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age at least 18 years
* Ischemic heart disease in medical history
* Planned on-pump coronary artery bypass graft (CABG) operation
* Signed informed consent by patient

Exclusion Criteria

* Age \<18 years
* Planned isolate valve or aortic operation
* Patient is in another study with an intervention
* Absence of signed informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tartu University Hospital

OTHER

Sponsor Role collaborator

North Estonia Medical Centre

OTHER

Sponsor Role collaborator

University of Tartu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Henery Kroon

Researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joel Starkopf, MD, PhD

Role: STUDY_DIRECTOR

Tartu University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

North Estonia Medical Centre

Tallinn, Harju, Estonia

Site Status

Tartu University Hospital

Tartu, Tartu, Estonia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Estonia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HN1160

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biomarkers in Acute Cardiac Care
NCT02355457 RECRUITING